212 related articles for article (PubMed ID: 18041880)
61. [Influence of tumor necrosis alpha blockade with infliximab on lipid profile in patients with active rheumatoid arthritis].
Pérez-Galán MJ; Salvatierra-Ossorio J; Cáliz-Cáliz R; Guzmán-Ubeda MA
Med Clin (Barc); 2006 May; 126(19):757. PubMed ID: 16759594
[No Abstract] [Full Text] [Related]
62. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009.
Furst DE; Keystone EC; Fleischmann R; Mease P; Breedveld FC; Smolen JS; Kalden JR; Braun J; Bresnihan B; Burmester GR; De Benedetti F; Dörner T; Emery P; Gibofsky A; Kavanaugh A; Kirkham B; Schiff MH; Sieper J; Singer N; Van Riel PL; Weinblatt ME; Weisman MH; Winthrop K
Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i2-29. PubMed ID: 19995740
[No Abstract] [Full Text] [Related]
63. Biologic therapy and pregnancy outcomes in women with rheumatic diseases.
Vinet E; Pineau C; Gordon C; Clarke AE; Bernatsky S
Arthritis Rheum; 2009 May; 61(5):587-92. PubMed ID: 19404999
[No Abstract] [Full Text] [Related]
64. The updated guidelines on the use of rituximab in rheumatoid arthritis.
Lopez-Olivo MA; Tayar JH; Suarez-Almazor ME
Rheumatology (Oxford); 2011 Dec; 50(12):2153-4. PubMed ID: 21546350
[No Abstract] [Full Text] [Related]
65. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011.
Furst DE; Keystone EC; Braun J; Breedveld FC; Burmester GR; De Benedetti F; Dörner T; Emery P; Fleischmann R; Gibofsky A; Kalden JR; Kavanaugh A; Kirkham B; Mease P; Sieper J; Singer NG; Smolen JS; Van Riel PL; Weisman MH; Winthrop K
Ann Rheum Dis; 2012 Apr; 71 Suppl 2():i2-45. PubMed ID: 22460137
[No Abstract] [Full Text] [Related]
66. New and promising treatments for rheumatoid arthritis.
Looney RJ; Stohl W
Am J Orthop (Belle Mead NJ); 2007 Jul; 36(7 Suppl):18-23. PubMed ID: 17694190
[No Abstract] [Full Text] [Related]
67. Cigarette smoking, TB, and TNF inhibitors.
Bieber J; Kavanaugh A
Ann Rheum Dis; 2003 Nov; 62(11):1118-9. PubMed ID: 14583580
[No Abstract] [Full Text] [Related]
68. Efficiency of potentiated antibodies to tumor necrosis factor-alpha (Artrofoon) in the therapy of patients with rheumatoid arthritis.
Petrov VI; Babaeva AR; Cherevkova EV; Epstein OI; Sergeeva SA
Bull Exp Biol Med; 2003 Jan; 135 Suppl 7():155-8. PubMed ID: 12949686
[TBL] [Abstract][Full Text] [Related]
69. [Prediction of efficacy of molecular targeted agents for rheumatoid arthritis].
Izumi K; Kameda H
Nihon Rinsho; 2012 Nov; 70 Suppl 8():658-63. PubMed ID: 23513918
[No Abstract] [Full Text] [Related]
70. Herpes zoster in the age of focused immunosuppressive therapy.
Whitley RJ; Gnann JW
JAMA; 2009 Feb; 301(7):774-5. PubMed ID: 19224757
[No Abstract] [Full Text] [Related]
71. Knee tuberculosis under rituximab therapy for rheumatoid arthritis.
Ottaviani S; Tiendrebeogo J; Choudat L; Gill G; Palazzo E; Meyer O; Dieudé P
Joint Bone Spine; 2013 Jul; 80(4):435-6. PubMed ID: 23238006
[No Abstract] [Full Text] [Related]
72. Comments on the original article by Soubrier et al. "Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis".
Seriolo B; Paoliono S; Ferrone C; Cutolo M
Joint Bone Spine; 2009 Jan; 76(1):117-8; author reply 118. PubMed ID: 19084458
[No Abstract] [Full Text] [Related]
73. Secondary immune deficiencies associated with biological therapeutics.
Lee SJ; Yedla P; Kavanaugh A
Curr Allergy Asthma Rep; 2003 Sep; 3(5):389-95. PubMed ID: 12906774
[TBL] [Abstract][Full Text] [Related]
74. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002).
Furst DE; Breedveld FC; Kalden JR; Smolen JS; Antoni CE; Bijlsma JW; Burmester GR; Cronstein B; Keystone EC; Kavanaugh A; Klareskog L
Ann Rheum Dis; 2002 Nov; 61 Suppl 2(Suppl 2):ii2-7. PubMed ID: 12379612
[No Abstract] [Full Text] [Related]
75. Monoclonal gammopathy of undetermined significance and anti-TNF-α treatment: comments on the article by Smale and Lawson.
Mielnik P; Hjelle AM; Szatkowski D
Scand J Rheumatol; 2013; 42(4):335-6. PubMed ID: 23829547
[No Abstract] [Full Text] [Related]
76. Infliximab-associated third nerve palsy.
Farukhi FI; Bollinger K; Ruggieri P; Lee MS
Arch Ophthalmol; 2006 Jul; 124(7):1055-7. PubMed ID: 16832034
[No Abstract] [Full Text] [Related]
77. The effects of TNF-alpha blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis.
Payet S; Pereira B; Soubrier M; Mathieu S
Semin Arthritis Rheum; 2012 Feb; 41(4):e4-5; author reply e6. PubMed ID: 22154222
[No Abstract] [Full Text] [Related]
78. Rheumatoid arthritis and the era of biologic therapy.
Malaviya AP; Ostör AJ
Inflammopharmacology; 2012 Apr; 20(2):59-69. PubMed ID: 22366810
[TBL] [Abstract][Full Text] [Related]
79. Are we content that risk of cancer is not appreciably increased after tumor necrosis factor inhibitor use? Comment on the article by Solomon et al.
Yazici H; Yazici Y
Arthritis Rheum; 2012 Jul; 64(7):2414; author reply 2414-5. PubMed ID: 22549846
[No Abstract] [Full Text] [Related]
80. The effects of TNF-alpha inhibitor therapy on arterial stiffness and endothelial dysfunction in rheumatoid arthritis: a meta-analysis.
Mathieu S; Couderc M; Pereira B; Soubrier M
Semin Arthritis Rheum; 2013 Dec; 43(3):e1-2. PubMed ID: 23810615
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
